News

“Receiving PRIME designation for sotatercept from the EMA mere weeks after the FDA granted it Breakthrough Therapy designation further strengthens our belief that sotatercept could eventually alter the

VIR-2703 is a result of the recently announced expansion of the firms’ multi-target existing collaboration for the development and commercialisation of RNAi therapeutics for infectious diseases. The partnership

LUNAR-COV19 utilizes Arcturus’ self-transcribing and replicating mRNA (STARR™) technology and the Company’s LUNAR® lipid-mediated delivery to produce an extraordinarily low dose, potential single shot COVID-19 vaccine. The manufacture

Junshi Biosciences, a Chinese biopharmaceutical company, is working to discover therapies to combat Covid-19 from the starting of the outbreak. The company has designed multiple neutralising antibodies and

Novartis announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Enerzair® Breezhaler® (QVM149;

CC-486 is an investigational oral hypomethylating agent, for the maintenance treatment of adult patients with AML, who achieved complete remission (CR) or CR with incomplete blood count recovery

The EUA will enable wider use of remdesivir for treating hospitalised patients with severe Covid-19 disease, enabling access to the medication at more hospitals across the US, said

The Government of Canada has granted the funds under Innovation, Science and Economic Development’s (ISED) Strategic Innovation Fund (SIF) to support the discovery of antibodies for use in

“The FDA’s final approval marks an important milestone for Banner and for patients living with relapsing-remitting multiple sclerosis,” said Franck Rousseau, M.D., Chief Executive Officer of Banner. “We